APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Single-target Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Research

FIC Single-target Drugs Industry Research Report 2026

28 December 2025139 pages

Choose your research edition.

Industry ResearchFIC Single-target Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Single-target Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal FIC Single-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Single-target Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Single-target Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global FIC Single-target Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for FIC Single-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for FIC Single-target Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for FIC Single-target Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of FIC Single-target Drugs include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Polarean lmaging and Phathom, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global FIC Single-target Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

FIC Single-target Drugs Market by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Polarean lmaging

Phathom

Marinus

Mallinckrodt

ImmunoGen

Immunocore

Gilead

Genentech

Dermavant Sciences

Boehringer Ingelheim

BMS

Agios

FIC Single-target Drugs Segment by Type

ALK2 Inhibitors

Citron Inhibitors

GCN2 Agonists

RORγ Covalent Inhibitors

Others

FIC Single-target Drugs Segment by Application

Hospital

Clinic

Other

FIC Single-target Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Single-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Single-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Single-target Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of FIC Single-target Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of FIC Single-target Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of FIC Single-target Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global FIC Single-target Drugs Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global FIC Single-target Drugs Sales (K Units) of Manufacturers (2021-2026) Table 7. Global FIC Single-target Drugs Sales Market Share by Manufacturers (2021-2026) Table 8. Global FIC Single-target Drugs Revenue of Manufacturers (2021-2026) Table 9. Global FIC Single-target Drugs Revenue Share by Manufacturers (2021-2026) Table 10. Global Market FIC Single-target Drugs Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global FIC Single-target Drugs Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of FIC Single-target Drugs, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of FIC Single-target Drugs, Product Type & Application Table 14. Global FIC Single-target Drugs Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global FIC Single-target Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Sanofi Company Information Table 19. Sanofi Business Overview Table 20. Sanofi FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Sanofi FIC Single-target Drugs Product Portfolio Table 22. Sanofi Recent Developments Table 23. Johnson & Johnson Company Information Table 24. Johnson & Johnson Business Overview Table 25. Johnson & Johnson FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Johnson & Johnson FIC Single-target Drugs Product Portfolio Table 27. Johnson & Johnson Recent Developments Table 28. Novartis Company Information Table 29. Novartis Business Overview Table 30. Novartis FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Novartis FIC Single-target Drugs Product Portfolio Table 32. Novartis Recent Developments Table 33. Merck Company Information Table 34. Merck Business Overview Table 35. Merck FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Merck FIC Single-target Drugs Product Portfolio Table 37. Merck Recent Developments Table 38. Roche Company Information Table 39. Roche Business Overview Table 40. Roche FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Roche FIC Single-target Drugs Product Portfolio Table 42. Roche Recent Developments Table 43. Eli Lilly Company Information Table 44. Eli Lilly Business Overview Table 45. Eli Lilly FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Eli Lilly FIC Single-target Drugs Product Portfolio Table 47. Eli Lilly Recent Developments Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Pfizer FIC Single-target Drugs Product Portfolio Table 52. Pfizer Recent Developments Table 53. Polarean lmaging Company Information Table 54. Polarean lmaging Business Overview Table 55. Polarean lmaging FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Polarean lmaging FIC Single-target Drugs Product Portfolio Table 57. Polarean lmaging Recent Developments Table 58. Phathom Company Information Table 59. Phathom Business Overview Table 60. Phathom FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Phathom FIC Single-target Drugs Product Portfolio Table 62. Phathom Recent Developments Table 63. Marinus Company Information Table 64. Marinus Business Overview Table 65. Marinus FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Marinus FIC Single-target Drugs Product Portfolio Table 67. Marinus Recent Developments Table 68. Mallinckrodt Company Information Table 69. Mallinckrodt Business Overview Table 70. Mallinckrodt FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Mallinckrodt FIC Single-target Drugs Product Portfolio Table 72. Mallinckrodt Recent Developments Table 73. ImmunoGen Company Information Table 74. ImmunoGen Business Overview Table 75. ImmunoGen FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. ImmunoGen FIC Single-target Drugs Product Portfolio Table 77. ImmunoGen Recent Developments Table 78. Immunocore Company Information Table 79. Immunocore Business Overview Table 80. Immunocore FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Immunocore FIC Single-target Drugs Product Portfolio Table 82. Immunocore Recent Developments Table 83. Gilead Company Information Table 84. Gilead Business Overview Table 85. Gilead FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Gilead FIC Single-target Drugs Product Portfolio Table 87. Gilead Recent Developments Table 88. Genentech Company Information Table 89. Genentech Business Overview Table 90. Genentech FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Genentech FIC Single-target Drugs Product Portfolio Table 92. Genentech Recent Developments Table 93. Dermavant Sciences Company Information Table 94. Dermavant Sciences Business Overview Table 95. Dermavant Sciences FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Dermavant Sciences FIC Single-target Drugs Product Portfolio Table 97. Dermavant Sciences Recent Developments Table 98. Boehringer Ingelheim Company Information Table 99. Boehringer Ingelheim Business Overview Table 100. Boehringer Ingelheim FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Boehringer Ingelheim FIC Single-target Drugs Product Portfolio Table 102. Boehringer Ingelheim Recent Developments Table 103. BMS Company Information Table 104. BMS Business Overview Table 105. BMS FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. BMS FIC Single-target Drugs Product Portfolio Table 107. BMS Recent Developments Table 108. Agios Company Information Table 109. Agios Business Overview Table 110. Agios FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Agios FIC Single-target Drugs Product Portfolio Table 112. Agios Recent Developments Table 113. Global FIC Single-target Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 114. Global FIC Single-target Drugs Sales by Region (2021-2026) & (K Units) Table 115. Global FIC Single-target Drugs Sales Market Share by Region (2021-2026) Table 116. Global FIC Single-target Drugs Sales by Region (2027-2032) & (K Units) Table 117. Global FIC Single-target Drugs Sales Market Share by Region (2027-2032) Table 118. Global FIC Single-target Drugs Revenue by Region (2021-2026) & (US$ Million) Table 119. Global FIC Single-target Drugs Revenue Market Share by Region (2021-2026) Table 120. Global FIC Single-target Drugs Revenue by Region (2027-2032) & (US$ Million) Table 121. Global FIC Single-target Drugs Revenue Market Share by Region (2027-2032) Table 122. North America FIC Single-target Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. North America FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 124. North America FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 125. North America FIC Single-target Drugs Revenue by Country (2021-2026) & (US$ Million) Table 126. North America FIC Single-target Drugs Revenue by Country (2027-2032) & (US$ Million) Table 127. Europe FIC Single-target Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Europe FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 129. Europe FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 130. Europe FIC Single-target Drugs Revenue by Country (2021-2026) & (US$ Million) Table 131. Europe FIC Single-target Drugs Revenue by Country (2027-2032) & (US$ Million) Table 132. Asia Pacific FIC Single-target Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 133. Asia Pacific FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 134. Asia Pacific FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 135. Asia Pacific FIC Single-target Drugs Revenue by Country (2021-2026) & (US$ Million) Table 136. Asia Pacific FIC Single-target Drugs Revenue by Country (2027-2032) & (US$ Million) Table 137. South America FIC Single-target Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 138. South America FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 139. South America FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 140. South America FIC Single-target Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. South America FIC Single-target Drugs Revenue by Country (2027-2032) & (US$ Million) Table 142. Middle East and Africa FIC Single-target Drugs Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 143. Middle East and Africa FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 144. Middle East and Africa FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 145. Middle East and Africa FIC Single-target Drugs Revenue by Country (2021-2026) & (US$ Million) Table 146. Middle East and Africa FIC Single-target Drugs Revenue by Country (2027-2032) & (US$ Million) Table 147. Global FIC Single-target Drugs Sales by Type (2021-2026) & (K Units) Table 148. Global FIC Single-target Drugs Sales by Type (2027-2032) & (K Units) Table 149. Global FIC Single-target Drugs Sales Market Share by Type (2021-2026) Table 150. Global FIC Single-target Drugs Sales Market Share by Type (2027-2032) Table 151. Global FIC Single-target Drugs Revenue by Type (2021-2026) & (US$ Million) Table 152. Global FIC Single-target Drugs Revenue by Type (2027-2032) & (US$ Million) Table 153. Global FIC Single-target Drugs Revenue Market Share by Type (2021-2026) Table 154. Global FIC Single-target Drugs Revenue Market Share by Type (2027-2032) Table 155. Global FIC Single-target Drugs Price by Type (2021-2026) & (US$/Unit) Table 156. Global FIC Single-target Drugs Price by Type (2027-2032) & (US$/Unit) Table 157. Global FIC Single-target Drugs Sales by Application (2021-2026) & (K Units) Table 158. Global FIC Single-target Drugs Sales by Application (2027-2032) & (K Units) Table 159. Global FIC Single-target Drugs Sales Market Share by Application (2021-2026) Table 160. Global FIC Single-target Drugs Sales Market Share by Application (2027-2032) Table 161. Global FIC Single-target Drugs Revenue by Application (2021-2026) & (US$ Million) Table 162. Global FIC Single-target Drugs Revenue by Application (2027-2032) & (US$ Million) Table 163. Global FIC Single-target Drugs Revenue Market Share by Application (2021-2026) Table 164. Global FIC Single-target Drugs Revenue Market Share by Application (2027-2032) Table 165. Global FIC Single-target Drugs Price by Application (2021-2026) & (US$/Unit) Table 166. Global FIC Single-target Drugs Price by Application (2027-2032) & (US$/Unit) Table 167. Key Raw Materials Table 168. Raw Materials Key Suppliers Table 169. FIC Single-target Drugs Distributors List Table 170. FIC Single-target Drugs Customers List Table 171. FIC Single-target Drugs Industry Trends Table 172. FIC Single-target Drugs Industry Drivers Table 173. FIC Single-target Drugs Industry Restraints Table 174. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. FIC Single-target Drugs Product Image Figure 5. Global FIC Single-target Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global FIC Single-target Drugs Market Size (2021-2032) & (US$ Million) Figure 7. Global FIC Single-target Drugs Sales (2021-2032) & (K Units) Figure 8. Global FIC Single-target Drugs Average Price (US$/Unit) & (2021-2032) Figure 9. ALK2 Inhibitors Product Image Figure 10. Citron Inhibitors Product Image Figure 11. GCN2 Agonists Product Image Figure 12. RORγ Covalent Inhibitors Product Image Figure 13. Others Product Image Figure 14. Hospital Product Image Figure 15. Clinic Product Image Figure 16. Other Product Image Figure 17. Global FIC Single-target Drugs Revenue Share by Manufacturers in 2025 Figure 18. Global Manufacturers of FIC Single-target Drugs, Manufacturing Sites & Headquarters Figure 19. Global Top 5 and 10 FIC Single-target Drugs Players Market Share by Revenue in 2025 Figure 20. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global FIC Single-target Drugs Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 22. Global FIC Single-target Drugs Sales by Region in 2025 Figure 23. Global FIC Single-target Drugs Revenue by Region in 2025 Figure 24. North America FIC Single-target Drugs Market Size by Country in 2025 Figure 25. North America FIC Single-target Drugs Sales Market Share by Country (2021-2032) Figure 26. North America FIC Single-target Drugs Revenue Market Share by Country (2021-2032) Figure 27. United States FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Canada FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 29. Mexico FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 30. Europe FIC Single-target Drugs Market Size by Country in 2025 Figure 31. Europe FIC Single-target Drugs Sales Market Share by Country (2021-2032) Figure 32. Europe FIC Single-target Drugs Revenue Market Share by Country (2021-2032) Figure 33. Germany FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. France FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. U.K. FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Italy FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Russia FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Spain FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Netherlands FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Switzerland FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Sweden FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Poland FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. Asia Pacific FIC Single-target Drugs Market Size by Country in 2025 Figure 44. Asia Pacific FIC Single-target Drugs Sales Market Share by Country (2021-2032) Figure 45. Asia Pacific FIC Single-target Drugs Revenue Market Share by Country (2021-2032) Figure 46. China FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. Japan FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. South Korea FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. India FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Australia FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Taiwan FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Southeast Asia FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 53. Southeast Asia FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 54. South America FIC Single-target Drugs Market Size by Country in 2025 Figure 55. South America FIC Single-target Drugs Sales Market Share by Country (2021-2032) Figure 56. South America FIC Single-target Drugs Revenue Market Share by Country (2021-2032) Figure 57. Brazil FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Argentina FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 59. Chile FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 60. Middle East and Africa FIC Single-target Drugs Market Size by Country in 2025 Figure 61. Middle East and Africa FIC Single-target Drugs Sales Market Share by Country (2021-2032) Figure 62. Middle East and Africa FIC Single-target Drugs Revenue Market Share by Country (2021-2032) Figure 63. Egypt FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. South Africa FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. Israel FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Türkiye FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 67. GCC Countries FIC Single-target Drugs Revenue Growth Rate (2021-2032) & (US$ Million) Figure 68. Global FIC Single-target Drugs Sales Market Share by Type (2021-2032) Figure 69. Global FIC Single-target Drugs Revenue Market Share by Type (2021-2032) Figure 70. Global FIC Single-target Drugs Price (US$/Unit) by Type (2021-2032) Figure 71. Global FIC Single-target Drugs Sales Market Share by Application (2021-2032) Figure 72. Global FIC Single-target Drugs Revenue Market Share by Application (2021-2032) Figure 73. Global FIC Single-target Drugs Price (US$/Unit) by Application (2021-2032) Figure 74. FIC Single-target Drugs Value Chain Figure 75. FIC Single-target Drugs Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. FIC Single-target Drugs Industry Opportunities and Challenges

Scope & coverage.

Types
  • ALK2 Inhibitors
  • Citron Inhibitors
  • GCN2 Agonists
  • RORγ Covalent Inhibitors
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Polarean lmaging
  • Phathom
  • Marinus
  • Mallinckrodt
  • ImmunoGen
  • Immunocore
  • Gilead
  • Genentech
  • Dermavant Sciences
  • Boehringer Ingelheim
  • BMS
  • Agios

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global FIC Single-target Drugs Market Size (2021-2032)
  4. 2.2.2 Global FIC Single-target Drugs Sales (2021-2032)
  5. 2.2.3 Global FIC Single-target Drugs Market Average Price (2021-2032)
  6. 2.3 FIC Single-target Drugs by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 ALK2 Inhibitors
  9. 2.3.3 Citron Inhibitors
  10. 2.3.4 GCN2 Agonists
  11. 2.3.5 RORγ Covalent Inhibitors
  12. 2.3.6 Others
  13. 2.4 FIC Single-target Drugs by Application
  14. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  15. 2.4.2 Hospital
  16. 2.4.3 Clinic
  17. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global FIC Single-target Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global FIC Single-target Drugs Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global FIC Single-target Drugs Revenue of Manufacturers (2021-2026)
  4. 3.4 Global FIC Single-target Drugs Average Price by Manufacturers (2021-2026)
  5. 3.5 Global FIC Single-target Drugs Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of FIC Single-target Drugs, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of FIC Single-target Drugs, Product Type & Application
  8. 3.8 Global Manufacturers of FIC Single-target Drugs, Established Date
  9. 3.9 Global FIC Single-target Drugs Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Sanofi
  2. 4.1.1 Sanofi Company Information
  3. 4.1.2 Sanofi Business Overview
  4. 4.1.3 Sanofi FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Sanofi FIC Single-target Drugs Product Portfolio
  6. 4.1.5 Sanofi Recent Developments
  7. 4.2 Johnson & Johnson
  8. 4.2.1 Johnson & Johnson Company Information
  9. 4.2.2 Johnson & Johnson Business Overview
  10. 4.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Johnson & Johnson FIC Single-target Drugs Product Portfolio
  12. 4.2.5 Johnson & Johnson Recent Developments
  13. 4.3 Novartis
  14. 4.3.1 Novartis Company Information
  15. 4.3.2 Novartis Business Overview
  16. 4.3.3 Novartis FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Novartis FIC Single-target Drugs Product Portfolio
  18. 4.3.5 Novartis Recent Developments
  19. 4.4 Merck
  20. 4.4.1 Merck Company Information
  21. 4.4.2 Merck Business Overview
  22. 4.4.3 Merck FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Merck FIC Single-target Drugs Product Portfolio
  24. 4.4.5 Merck Recent Developments
  25. 4.5 Roche
  26. 4.5.1 Roche Company Information
  27. 4.5.2 Roche Business Overview
  28. 4.5.3 Roche FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Roche FIC Single-target Drugs Product Portfolio
  30. 4.5.5 Roche Recent Developments
  31. 4.6 Eli Lilly
  32. 4.6.1 Eli Lilly Company Information
  33. 4.6.2 Eli Lilly Business Overview
  34. 4.6.3 Eli Lilly FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Eli Lilly FIC Single-target Drugs Product Portfolio
  36. 4.6.5 Eli Lilly Recent Developments
  37. 4.7 Pfizer
  38. 4.7.1 Pfizer Company Information
  39. 4.7.2 Pfizer Business Overview
  40. 4.7.3 Pfizer FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Pfizer FIC Single-target Drugs Product Portfolio
  42. 4.7.5 Pfizer Recent Developments
  43. 4.8 Polarean lmaging
  44. 4.8.1 Polarean lmaging Company Information
  45. 4.8.2 Polarean lmaging Business Overview
  46. 4.8.3 Polarean lmaging FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Polarean lmaging FIC Single-target Drugs Product Portfolio
  48. 4.8.5 Polarean lmaging Recent Developments
  49. 4.9 Phathom
  50. 4.9.1 Phathom Company Information
  51. 4.9.2 Phathom Business Overview
  52. 4.9.3 Phathom FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Phathom FIC Single-target Drugs Product Portfolio
  54. 4.9.5 Phathom Recent Developments
  55. 4.10 Marinus
  56. 4.10.1 Marinus Company Information
  57. 4.10.2 Marinus Business Overview
  58. 4.10.3 Marinus FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Marinus FIC Single-target Drugs Product Portfolio
  60. 4.10.5 Marinus Recent Developments
  61. 4.11 Mallinckrodt
  62. 4.11.1 Mallinckrodt Company Information
  63. 4.11.2 Mallinckrodt Business Overview
  64. 4.11.3 Mallinckrodt FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Mallinckrodt FIC Single-target Drugs Product Portfolio
  66. 4.11.5 Mallinckrodt Recent Developments
  67. 4.12 ImmunoGen
  68. 4.12.1 ImmunoGen Company Information
  69. 4.12.2 ImmunoGen Business Overview
  70. 4.12.3 ImmunoGen FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 ImmunoGen FIC Single-target Drugs Product Portfolio
  72. 4.12.5 ImmunoGen Recent Developments
  73. 4.13 Immunocore
  74. 4.13.1 Immunocore Company Information
  75. 4.13.2 Immunocore Business Overview
  76. 4.13.3 Immunocore FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Immunocore FIC Single-target Drugs Product Portfolio
  78. 4.13.5 Immunocore Recent Developments
  79. 4.14 Gilead
  80. 4.14.1 Gilead Company Information
  81. 4.14.2 Gilead Business Overview
  82. 4.14.3 Gilead FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 Gilead FIC Single-target Drugs Product Portfolio
  84. 4.14.5 Gilead Recent Developments
  85. 4.15 Genentech
  86. 4.15.1 Genentech Company Information
  87. 4.15.2 Genentech Business Overview
  88. 4.15.3 Genentech FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Genentech FIC Single-target Drugs Product Portfolio
  90. 4.15.5 Genentech Recent Developments
  91. 4.16 Dermavant Sciences
  92. 4.16.1 Dermavant Sciences Company Information
  93. 4.16.2 Dermavant Sciences Business Overview
  94. 4.16.3 Dermavant Sciences FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Dermavant Sciences FIC Single-target Drugs Product Portfolio
  96. 4.16.5 Dermavant Sciences Recent Developments
  97. 4.17 Boehringer Ingelheim
  98. 4.17.1 Boehringer Ingelheim Company Information
  99. 4.17.2 Boehringer Ingelheim Business Overview
  100. 4.17.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 4.17.4 Boehringer Ingelheim FIC Single-target Drugs Product Portfolio
  102. 4.17.5 Boehringer Ingelheim Recent Developments
  103. 4.18 BMS
  104. 4.18.1 BMS Company Information
  105. 4.18.2 BMS Business Overview
  106. 4.18.3 BMS FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 4.18.4 BMS FIC Single-target Drugs Product Portfolio
  108. 4.18.5 BMS Recent Developments
  109. 4.19 Agios
  110. 4.19.1 Agios Company Information
  111. 4.19.2 Agios Business Overview
  112. 4.19.3 Agios FIC Single-target Drugs Sales, Revenue and Gross Margin (2021-2026)
  113. 4.19.4 Agios FIC Single-target Drugs Product Portfolio
  114. 4.19.5 Agios Recent Developments
5 Global FIC Single-target Drugs Market Scenario by Region
  1. 5.1 Global FIC Single-target Drugs Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global FIC Single-target Drugs Sales by Region: 2021-2032
  3. 5.2.1 Global FIC Single-target Drugs Sales by Region: 2021-2026
  4. 5.2.2 Global FIC Single-target Drugs Sales by Region: 2027-2032
  5. 5.3 Global FIC Single-target Drugs Revenue by Region: 2021-2032
  6. 5.3.1 Global FIC Single-target Drugs Revenue by Region: 2021-2026
  7. 5.3.2 Global FIC Single-target Drugs Revenue by Region: 2027-2032
  8. 5.4 North America FIC Single-target Drugs Market Facts & Figures by Country
  9. 5.4.1 North America FIC Single-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America FIC Single-target Drugs Sales by Country (2021-2032)
  11. 5.4.3 North America FIC Single-target Drugs Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe FIC Single-target Drugs Market Facts & Figures by Country
  16. 5.5.1 Europe FIC Single-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe FIC Single-target Drugs Sales by Country (2021-2032)
  18. 5.5.3 Europe FIC Single-target Drugs Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific FIC Single-target Drugs Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific FIC Single-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific FIC Single-target Drugs Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific FIC Single-target Drugs Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America FIC Single-target Drugs Market Facts & Figures by Country
  41. 5.7.1 South America FIC Single-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America FIC Single-target Drugs Sales by Country (2021-2032)
  43. 5.7.3 South America FIC Single-target Drugs Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa FIC Single-target Drugs Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa FIC Single-target Drugs Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa FIC Single-target Drugs Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa FIC Single-target Drugs Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global FIC Single-target Drugs Sales by Type (2021-2032)
  2. 6.1.1 Global FIC Single-target Drugs Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global FIC Single-target Drugs Sales Market Share by Type (2021-2032)
  4. 6.2 Global FIC Single-target Drugs Revenue by Type (2021-2032)
  5. 6.2.1 Global FIC Single-target Drugs Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global FIC Single-target Drugs Revenue Market Share by Type (2021-2032)
  7. 6.3 Global FIC Single-target Drugs Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global FIC Single-target Drugs Sales by Application (2021-2032)
  2. 7.1.1 Global FIC Single-target Drugs Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global FIC Single-target Drugs Sales Market Share by Application (2021-2032)
  4. 7.2 Global FIC Single-target Drugs Revenue by Application (2021-2032)
  5. 7.2.1 Global FIC Single-target Drugs Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global FIC Single-target Drugs Revenue Market Share by Application (2021-2032)
  7. 7.3 Global FIC Single-target Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 FIC Single-target Drugs Value Chain Analysis
  2. 8.1.1 FIC Single-target Drugs Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 FIC Single-target Drugs Production Mode & Process
  5. 8.2 FIC Single-target Drugs Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 FIC Single-target Drugs Distributors
  8. 8.2.3 FIC Single-target Drugs Customers
9 Global FIC Single-target Drugs Analyzing Market Dynamics
  1. 9.1 FIC Single-target Drugs Industry Trends
  2. 9.2 FIC Single-target Drugs Industry Drivers
  3. 9.3 FIC Single-target Drugs Industry Opportunities and Challenges
  4. 9.4 FIC Single-target Drugs Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst